Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2010-12-14FDA Approved: VENLAFAXINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' generic venlafaxine via an Original Application (ANDA). It is indicated for major depressive disorder,…
-
FDA approval · 2010-12-10FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) submitted by NorthStar Rx LLC. This action represents an a…
-
FDA approval · 2010-10-15FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride (generic) from Zydus Lifesciences Limited, authorizing a generic paroxe…
-
CLINICAL_TRIALS trial_result · 2010-10-08Clinical Trial Update: Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325 [Phase 2]
This update reports Phase 2 proof-of-concept results for AZD7325 in patients with generalized anxiety disorder.
-
CLINICAL_TRIALS trial_result · 2010-09-29Clinical Trial Update: Exercise Training for the Treatment of Generalized Anxiety Disorder [NA]
A completed clinical trial evaluated exercise training as a treatment for Generalized anxiety disorder, with results posted in 2010.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-08-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic venlafaxine hydrochloride under an Original Application. It is indicated for major depre…
-
FDA approval · 2010-08-04FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Venlafaxine hydrochloride by Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2010-06-30Clinical Trial Update: ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder [NA]
A completed clinical trial evaluating ERP N1 as a predictor of treatment response in Generalized Anxiety Disorder. The study was sponsored b…
-
FDA approval · 2010-06-28FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's venlafaxine hydrochloride as an Original Application generic (ANDA). The approval enables a generic version of venlafaxi…
-
FDA approval · 2010-06-21FDA Approved: PAROXETINE HYDROCHLORIDE — Original Application (Oxford Pharmaceuticals, LLC)
FDA approved Paroxetine hydrochloride as an Original Application (ANDA) generic for Oxford Pharmaceuticals, LLC.
-
FDA approval · 2010-06-15FDA Approved: LORAZEPAM — Original Application (Pharmaceutical Associates, Inc.)
FDA approved Lorazepam under an Original Application for an ANDA held by Pharmaceutical Associates, Inc., establishing a generic version of …
-
CLINICAL_TRIALS trial_result · 2010-05-20Clinical Trial Update: Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder [Phase 2]
Phase 2 trial assessing the efficacy, safety, and tolerability of XBD173 in patients with generalized anxiety disorder. The study status is …
-
FDA approval · 2010-04-07FDA Approved: VENLAFAXINE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original application for Venlafaxine hydrochloride, a generic version of venlafaxine.
-
FDA approval · 2010-03-25FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for paroxetine hydrochloride hemihydrate from Mylan Pharmaceuticals Inc., advancing the generic …
-
FDA approval · 2010-03-25FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for paroxetine hydrochloride from Apotex Corp., granting approval for an additional generic product.
-
FDA approval · 2010-03-16FDA Approved: ALPRAZOLAM — Original Application (Actavis Pharma, Inc.)
FDA approves Actavis Pharma, Inc.'s generic alprazolam through an Original Application (ANDA).
-
FDA approval · 2010-03-15FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc. under ANDA076690.
-
FDA approval · 2010-03-11FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application submitted by BluePoint Laboratories for venlafaxine (venlafaxine hydrochloride) as a generic product…
-
CLINICAL_TRIALS trial_result · 2010-03-02Clinical Trial Update: Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety [Phase 4]
This update reports the completion of a Phase 4 clinical trial evaluating black cohosh as an alternative therapy for menopause-related anxie…
-
FDA approval · 2010-02-26FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Venlafaxine hydrochloride from Dr. Reddy's Laboratories Limited under an ANDA. This confirms reg…
-
CLINICAL_TRIALS trial_result · 2010-02-19Clinical Trial Update: A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder [Phase 2]
A completed Phase 2 randomized trial evaluated PD 0332334 in combination with extended-release alprazolam versus placebo in Generalized Anxi…
-
CLINICAL_TRIALS trial_result · 2010-02-17Clinical Trial Update: Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body [Phase 1]
Phase 1 pharmacokinetic study evaluating whether cimetidine affects the elimination of Pfizer's PD-0332334; the trial was terminated.
-
CLINICAL_TRIALS trial_result · 2010-02-17Clinical Trial Update: Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time [Phase 1]
Phase 1 pharmacokinetic study evaluating how PD 0332334 and metformin are eliminated when administered together, sponsored by Pfizer; the tr…
-
FDA approval · 2010-01-06FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2009-12-02Clinical Trial Update: Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD). [Phase 3]
Phase 3 clinical trial update for pregabalin in generalized anxiety disorder has completed with results posted in 2009.